Anterior|Siguiente

Explorando el efecto de la cápsula pulmonar Qibai Ping en la reestructuración vascular pulmonar en diferentes etapas de la broncopneumopatía crónica obstructiva basada en la vía de señalización TLR4/NF-κB

  • role： First author第一作者
  • Affiliation：

    Anhui University of Chinese Medicine，Hefei 230038，China

  • Email：1195263773@qq.com
  • Introduction：张璐，在读博士，从事中医药防治呼吸系统疾病研究，E-mail：1195263773@qq.com
ZHANG Lu1,  
  • Affiliation：

    The First Affiliated Hospital of Anhui University of Chinese Medicine，Hefei 230031，China

FANG Li2,  
  • Affiliation：

    Anhui University of Chinese Medicine，Hefei 230038，China

XU Shuyu1,  
  • Affiliation：

    Anhui University of Chinese Medicine，Hefei 230038，China

LIANG Xue1,  
  • Affiliation：

    Anhui University of Chinese Medicine，Hefei 230038，China

ZHU Jie1,  
  • Affiliation：

    The First Affiliated Hospital of Anhui University of Chinese Medicine，Hefei 230031，China

TONG Xiangli2,  
  • role： Corresponding author通信作者
  • Affiliation：

    The First Affiliated Hospital of Anhui University of Chinese Medicine，Hefei 230031，China

    Anhui Provincial Key Laboratory of Application and Transformation of Traditional Chinese Medicine in Prevention and Treatment of Major Pulmonary Diseases，Hefei 230031，China

  • Email：ahzyfb@sina.com
  • Introduction：李泽庚，教授，主任医师，博士生导师，从事中医药防治呼吸系统疾病研究，E-mail：ahzyfb@sina.com
LI Zegeng23*

resumen

El objetivo de este estudio fue explorar el efecto de la cápsula pulmonar Qibai Ping en la reestructuración vascular pulmonar en ratas con EPOC en diferentes etapas y analizar su posible mecanismo de acción. Las ratas SD macho se dividieron al azar en un grupo normal, un grupo modelo de EPOC temprana, un grupo modelo de EPOC tardía, un grupo de intervención temprana de alta dosis, un grupo de intervención tardía de alta dosis, un grupo de intervención temprana de baja dosis, un grupo de intervención tardía de baja dosis, un grupo de intervención PDTC temprano, y un grupo de intervención PDTC tardío, cada uno compuesto por 15 ratas. Se construyó un modelo de rata EPOC temprana mediante la inhalación de humo de cigarrillo combinada con una instilación intratraqueal de lipopolisacárido (LPS), y un modelo de rata EPOC tardía mediante la instilación intratraqueal de LPS combinada con la inhalación de humo de cigarrillo y oxígeno bajo. Excepto el grupo normal, los otros grupos recibieron una instilación intratraqueal de LPS el primer día y el día 14 del experimento, una fumigación de cigarrillo durante 1 hora al día, y comenzaron a tomar el medicamento el día 15, una vez al día, durante 40 semanas. Los grupos de alta y baja dosis de la cápsula Qibai Ping se administraron a dosis de 1g/kg y 250mg/kg de peso corporal de las ratas respectivamente, y el PDTC se administró por inyección intraperitoneal a una dosis de 100mg/kg. Las ratas de los grupos de modelos de EPOC tardía fueron sometidas a una baja concentración de oxígeno durante 6 horas al día durante la 5ª y 6ª semana. Las funciones pulmonares de las ratas, la presión arterial media...

palabra clave

Cápsula pulmonar de Qibai Ping; enfermedad pulmonar obstructiva crónica (EPOC); reestructuración vascular pulmonar; transición intersticial del endotelio; vía de señalización Toll-4/receptor nuclear-κB (TLR4/NF-κB)

References

  1. 1.
    Global Initiative for Chronic Obstructive Lung Disease.Global strategy for the diagnosis，management，and prevention of chronic obstructive pulmonary disease（2024 report）［EB/OL］.（2023-11-15）［2024-11-08］..
  2. 2.
    WANG C，XU J，YANG L，et al.Prevalence and risk factors of chronic obstructive pulmonary disease in China（the China Pulmonary Health［CPH］ study）：A national cross-sectional study［J］.Lancet，2018，391（10131）：1706-1717.
  3. 3.
    MINAI O A，CHAOUAT A，ADNOT S.Pulmonary hypertension in COPD：Epidemiology，significance，and management：Pulmonary vascular disease：The global perspective［J］.Chest，2010，137（6 Suppl）：39S-51S.
  4. 4.
    CHAI T，QIU C，XIAN Z，et al.A narrative review of research advances in hypoxic pulmonary hypertension［J］.Ann Transl Med，2022，10（4）：230.
  5. 5.
    GOEL K，EGERSDORF N，GILL A，et al.Characterization of pulmonary vascular remodeling and microrna-126-targets in copd-pulmonary hypertension［J］.Respir Res，2022，23（1）：349.
  6. 6.
    CHU X，AHMADVAND N，ZHANG J S，et al.Evidence for multiple origins of de novo formed vascular smooth muscle cells in pulmonary hypertension：Challenging the dominant model of pre-existing smooth muscle expansion［J］.Int J Environ Res Public Health，2021，18（16）：8584.
  7. 7.
    YIN T T，LI Z G，WANG C B，et al.Clinical research of Qibai Pingfei capsule on "Lung Qi Deficiency and Missing" COPD pulmonary vasoconstriction regulation function［J］.Clin J Tradit Chin Med，2018，30（8）：1459-1464.
  8. 8.
    WANG X L，GAO Y T，ZHU J，et al.Bioinformatics analysis of the molecular mechanism of Qibai Pingfei capsule in the regulation of chronic obstructive pulmonary disease related immune cells［J］.Chin J Cell Mol Immunol，2022，38（11）：961-966.
  9. 9.
    PENG B，LI Z G，WANG C B，et al.The effect of lack oxygen on Qibai Pingfei capsule curedpah based COPD's patients［J］.Acta Chin Med，2011，26（9）：1037-1039.
  10. 10.
    TONG X L.Retrospective analysis on the clinical efficacy of 367 cases COPD and effect of Qibai Pingfei capsule medicated serum on apoptosis of rat pulmonary artery smooth muscle cells under hypoxia［D］.Heifei：Anhui Univ Chin Med，2016.
  11. 11.
    ZHANG L，TONG X L，WANG X L，et al.Qibai Pingfei capsule promotes the apoptosis of pulmonary artery smooth muscle cells in rats with hypoxia by inhibiting the PI3K/Akt pathway［J］.J Anhui Univ Chin Med，2022，41（2）：55-60.
  12. 12.
    FANG L，WANG C B，WANG J Q，et al.Influence of Qibai Pingfei capsule on expression of Rho-kinase in pulmonary vascular remodeling of COPD rats with syndrome of phlegm and blood stasis obstructing lung［J］.China J Tradit Chin Med Pharm，2016，31（1）：229-232.
  13. 13.
    ZHENG L L，WANG J Q，LI Z G，et al.Correlation between micro-accumulation in lung collateral vessels and pulmonary vessel remodeling of chronic obstructive pulmonary disease［J］.J Changchun Univ Chin Med，2017，33（1）：7-9.
  14. 14.
    BLANCO I，TURA-CEIDE O，PEINADO V I，et al.Updated perspectives on pulmonary hypertension in copd［J］.Int J Chron Obstruct Pulmon Dis，2020，15：1315-1324.
  15. 15.
    STENMARK K R，FAGAN K A，FRID M G.Hypoxia-induced pulmonary vascular remodeling：Cellular and molecular mechanisms［J］.Circ Res，2006，99（7）：675-691.
  16. 16.
    WANG R，WANG Z P.Research advances in pulmonary vascular remodeling mechanism of hypoxic pulmonary hypertension［J］.Int J Anesthesiol Resuscitat，2020，41（3）：301-304.
  17. 17.
    ALQARNI A A，ALDHAHIR A M，ALGHAMDI S A，et al.Role of prostanoids，nitric oxide and endothelin pathways in pulmonary hypertension due to copd［J］.Front Med（Lausanne），2023，10：1275684.
  18. 18.
    FERRER E，PEINADO V I，CASTAÑEDA J，et al.Effects of cigarette smoke and hypoxia on pulmonary circulation in the guinea pig［J］.Eur Respir J，2011，38（3）：617-627.
  19. 19.
    BHATTARAI P，LU W，MARKOS J，et al.Increased arterial remodelling in smokers and mild-moderate COPD patients are indicative of potential early onset of pulmonary hypertension［J］.Eur Respir J，2021，58：Suppl.65，OA1216.
  20. 20.
    KRÜGER-GENGE A，BLOCKI A，FRANKE R P，et al.Vascular endothelial cell biology：An update［J］.Int J Mol Sci，2019，20（18）：4411.
  21. 21.
    PRESTON I R.Clinical perspective of hypoxia-mediated pulmonary hypertension［J］.Antioxid Redox Signal，2007，9（6）：711-721.
  22. 22.
    BRODSKAYA T A，NEVZOROVA V A，VASILEVA M S，et al.Endothelium-related and neuro-mediated mechanisms of emphysema development in chronic obstructive pulmonary disease［J］.Ter Arkh，2020，92（3）：116-124.
  23. 23.
    YANG Q F，QU J L，ZHAO H L，et al.Mechanism of medicated serum of Buyang Huanwutang in inhibiting endothelial-to-mesenchymal transition of human pulmonary artery endothelial cells based on Wnt1/β-catenin signaling pathway［J］.Chin J Exp Tradit Med Form，2024，30（7）：49-58.
  24. 24.
    BHATTARAI P，LU W，HARDIKAR A，et al.TGF-β1，Smad and β-catenin in pulmonary arteries of smokers，patients with small airway disease and copd：Potential drivers of endmt［J］.Clin Sci（Lond），2024，138（17）：1055-1070.
  25. 25.
    ZUO Z T，MA Y，SUN Y，et al.role of TLR4/NF-κB signalling pathway in pulmonary arterial hypertension in patients with chronic obstructive pulmonary disease［J］.J Coll Physicians Surg Pak，2020，30（6）：568-573.
  26. 26.
    SHI Y L，WANG Y C，YANG Z，et al.Research progress on classic Chinese medicine compounds and monomers in the treatment of chronic obstructive pulmonary disease［J］.World Chin Med，2024，19（11）：1693-1700.
  27. 27.
    WANG P，ZENG Y L，XIONG W，et al.Expression and significance of TLR4/NF-κB in pulmonary vascular remodeling in smoking rats［J］.Chin J Pathophysiol，2016，32（11）：2083-2087.
  28. 28.
    KIM R，KIM M，JEONG S，et al.Melatonin alleviates myocardial dysfunction through inhibition of endothelial-to-mesenchymal transition via the NF-κB pathway［J］.J Pineal Res，2024，76（4）：E12958.
  29. 29.
    YUN E，KOOK Y，YOO K H，et al.Endothelial to mesenchymal transition in pulmonary vascular diseases［J］.Biomedicines，2020，8（12）：639.
  30. 30.
    YANG L X，JIA Q Y，CHEN Y，et al.The role and clinical significance of Toll like receptor 2，4/MyD88/NF-κB signaling pathway and related molecules in the pathogenesis of COPD［J］.Med J West China，2020，32（12）：1811-1815，1820.
  31. 31.
    WANG C B，WANG J Q，LI Z G，et al.Effect of TCM compound on NF-κB in rats with chronic obstructive pulmonary disease model［J］.Clin J Tradit Chin Med，2014，26（1）：49-50.

Leer el texto completo

The above content is generated by Large Model Translation. The translated content is for reference only. We do not assume any commercial or legal responsibilty for any consequences arising from the use of our website